614 related articles for article (PubMed ID: 33674391)
1. COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels.
Szendrey M; Guo J; Li W; Yang T; Zhang S
J Pharmacol Exp Ther; 2021 May; 377(2):265-272. PubMed ID: 33674391
[TBL] [Abstract][Full Text] [Related]
2. Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.
Zequn Z; Yujia W; Dingding Q; Jiangfang L
Eur J Pharmacol; 2021 Feb; 893():173813. PubMed ID: 33345848
[TBL] [Abstract][Full Text] [Related]
3. Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learned.
Sultan S; Acharya Y
Vascular; 2021 Apr; 29(2):220-227. PubMed ID: 32691699
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of gefitinib-induced QT prolongation.
Jie LJ; Li YD; Zhang HQ; Mao L; Xie HB; Zhou FG; Zhou TL; Xie D; Lin JL; Li GY; Cai BN; Zhang YH; Wang Y
Eur J Pharmacol; 2021 Nov; 910():174441. PubMed ID: 34474028
[TBL] [Abstract][Full Text] [Related]
5. Fentanyl-Induced Block of hERG Channels Is Exacerbated by Hypoxia, Hypokalemia, Alkalosis, and the Presence of hERG1b.
Tschirhart JN; Zhang S
Mol Pharmacol; 2020 Oct; 98(4):508-517. PubMed ID: 32321735
[TBL] [Abstract][Full Text] [Related]
6. Interaction between the cardiac rapidly (IKr) and slowly (IKs) activating delayed rectifier potassium channels revealed by low K+-induced hERG endocytic degradation.
Guo J; Wang T; Yang T; Xu J; Li W; Fridman MD; Fisher JT; Zhang S
J Biol Chem; 2011 Oct; 286(40):34664-74. PubMed ID: 21844197
[TBL] [Abstract][Full Text] [Related]
7. Hydroxychloroquine Attenuates hERG Channel by Promoting the Membrane Channel Degradation: Computational Simulation and Experimental Evidence for QT-Interval Prolongation with Hydroxychloroquine Treatment.
Wang X; Feng Y; Liu S; Liu J; Pan S; Wei L; Ma Y; Liu Z; Xing Y; Wang J; Cui Q; Zhang Y; Wang T; Cai C
Cardiology; 2023; 148(4):310-323. PubMed ID: 37231805
[TBL] [Abstract][Full Text] [Related]
8. Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.
Choi SW; Shin JS; Park SJ; Jung E; Park YG; Lee J; Kim SJ; Park HJ; Lee JH; Park SM; Moon SH; Ban K; Go YY
Antiviral Res; 2020 Dec; 184():104955. PubMed ID: 33091434
[TBL] [Abstract][Full Text] [Related]
9. Assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine using the CiPA concept.
Thomet U; Amuzescu B; Knott T; Mann SA; Mubagwa K; Radu BM
Eur J Pharmacol; 2021 Dec; 913():174632. PubMed ID: 34785211
[TBL] [Abstract][Full Text] [Related]
10. Risk Assessment of Drug-Induced Long QT Syndrome for Some COVID-19 Repurposed Drugs.
Michaud V; Dow P; Al Rihani SB; Deodhar M; Arwood M; Cicali B; Turgeon J
Clin Transl Sci; 2021 Jan; 14(1):20-28. PubMed ID: 32888379
[TBL] [Abstract][Full Text] [Related]
11. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Wang M; Cao R; Zhang L; Yang X; Liu J; Xu M; Shi Z; Hu Z; Zhong W; Xiao G
Cell Res; 2020 Mar; 30(3):269-271. PubMed ID: 32020029
[No Abstract] [Full Text] [Related]
12. Anti-Ro52 antibody acts on the S5-pore linker of hERG to chronically reduce channel expression.
Szendrey J; Lamothe SM; Vanner S; Guo J; Yang T; Li W; Davis J; Joneja M; Baranchuk A; Zhang S
Cardiovasc Res; 2019 Aug; 115(10):1500-1511. PubMed ID: 30544220
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells.
Traebert M; Dumotier B; Meister L; Hoffmann P; Dominguez-Estevez M; Suter W
Eur J Pharmacol; 2004 Jan; 484(1):41-8. PubMed ID: 14729380
[TBL] [Abstract][Full Text] [Related]
14. Structural implications of hERG K
Helliwell MV; Zhang Y; El Harchi A; Du C; Hancox JC; Dempsey CE
J Biol Chem; 2018 May; 293(18):7040-7057. PubMed ID: 29545312
[TBL] [Abstract][Full Text] [Related]
15. Differential Effects of Remdesivir and Lumacaftor on Homomeric and Heteromeric hERG Channels.
Campagna N; Wall E; Lee K; Guo J; Li W; Yang T; Baranchuk A; El-Diasty M; Zhang S
Mol Pharmacol; 2023 Oct; 104(4):164-173. PubMed ID: 37419691
[TBL] [Abstract][Full Text] [Related]
16. Block of wild-type and inactivation-deficient human ether-a-go-go-related gene K+ channels by halofantrine.
Sánchez-Chapula JA; Navarro-Polanco RA; Sanguinetti MC
Naunyn Schmiedebergs Arch Pharmacol; 2004 Dec; 370(6):484-91. PubMed ID: 15558243
[TBL] [Abstract][Full Text] [Related]
17. Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century.
Sanghai N; Shafiq K; Tranmer GK
Mini Rev Med Chem; 2021; 21(1):3-9. PubMed ID: 32838716
[TBL] [Abstract][Full Text] [Related]
18. Facilitation of
Furutani K; Tsumoto K; Chen IS; Handa K; Yamakawa Y; Sack JT; Kurachi Y
J Gen Physiol; 2019 Feb; 151(2):214-230. PubMed ID: 30674563
[TBL] [Abstract][Full Text] [Related]
19. Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking.
Zhang Y; Colenso CK; El Harchi A; Cheng H; Witchel HJ; Dempsey CE; Hancox JC
Biochem Pharmacol; 2016 Aug; 113():24-35. PubMed ID: 27256139
[TBL] [Abstract][Full Text] [Related]
20. Cyclovirobuxine D inhibits the currents of HERG potassium channels stably expressed in HEK293 cells.
Zhao J; Wang Q; Xu J; Zhao J; Liu G; Peng S
Eur J Pharmacol; 2011 Jun; 660(2-3):259-67. PubMed ID: 21497594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
